Repligen (RGEN) Competitors

Qiagen (NYSE:QGEN) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, community ranking, earnings, institutional ownership, media sentiment and dividends.

Is QGEN or RGEN more profitable?

Qiagen has a net margin of 17.38% compared to Qiagen's net margin of 2.44%. Repligen's return on equity of 12.59% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	17.38%	12.59%	7.67%
Repligen	2.44%	3.95%	2.90%

Which has more volatility & risk, QGEN or RGEN?

Qiagen has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Comparatively, Repligen has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.

Do insiders & institutionals believe in QGEN or RGEN?

70.0% of Qiagen shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 1.2% of Repligen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts rate QGEN or RGEN?

Qiagen presently has a consensus price target of $51.05, suggesting a potential upside of 16.24%. Repligen has a consensus price target of $194.00, suggesting a potential upside of 37.79%. Given Qiagen's stronger consensus rating and higher probable upside, analysts plainly believe Repligen is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Repligen	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

Which has higher valuation and earnings, QGEN or RGEN?

Qiagen has higher revenue and earnings than Repligen. Qiagen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$1.97B	5.10	$341.30M	$1.49	29.45
Repligen	$638.76M	12.32	$41.58M	$0.25	563.18

Does the MarketBeat Community prefer QGEN or RGEN?

Repligen received 156 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.07% of users gave Repligen an outperform vote while only 60.99% of users gave Qiagen an outperform vote.

Company	Underperform	Outperform
Qiagen	Outperform Votes 247 60.99%	Underperform Votes 158 39.01%
Repligen	Outperform Votes 403 68.07%	Underperform Votes 189 31.93%

Does the media refer more to QGEN or RGEN?

In the previous week, Repligen had 11 more articles in the media than Qiagen. MarketBeat recorded 14 mentions for Repligen and 3 mentions for Qiagen. Repligen's average media sentiment score of 0.91 beat Qiagen's score of 0.78 indicating that Qiagen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Repligen beats Qiagen on 10 of the 18 factors compared between the two stocks.